Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK + DLBCL) is a rare and highly aggressive mature B-cell lymphoma with poor responses to conventional chemotherapy and no established standard treatment. Although ALK inhibitors have shown potential activity in ALK-rearranged malignancies, their clinical utility and optimal sequencing in ALK + DLBCL remain unclear.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
